Giulia Carli

ORCID: 0000-0001-7216-2031
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Parkinson's Disease Mechanisms and Treatments
  • Neurological disorders and treatments
  • Functional Brain Connectivity Studies
  • Pain Management and Placebo Effect
  • Sleep and Wakefulness Research
  • Dementia and Cognitive Impairment Research
  • Alzheimer's disease research and treatments
  • EEG and Brain-Computer Interfaces
  • Advanced MRI Techniques and Applications
  • Restless Legs Syndrome Research
  • Erythrocyte Function and Pathophysiology
  • Advanced Neuroimaging Techniques and Applications
  • Memory and Neural Mechanisms
  • Heart Rate Variability and Autonomic Control
  • Neuroscience and Neuropharmacology Research
  • Lysosomal Storage Disorders Research
  • Genetic Neurodegenerative Diseases
  • Neuroscience of respiration and sleep
  • Medical Imaging Techniques and Applications
  • Long-Term Effects of COVID-19
  • Cellular transport and secretion
  • Diet and metabolism studies
  • Attention Deficit Hyperactivity Disorder
  • Blood groups and transfusion
  • Neurobiology of Language and Bilingualism

University of Michigan
2023-2025

University Medical Center Groningen
2022-2025

University of Groningen
2022-2025

Michigan Medicine
2024

Vita-Salute San Raffaele University
2017-2022

Istituti di Ricovero e Cura a Carattere Scientifico
2018-2022

Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2018-2022

San Raffaele University of Rome
2019

Abstract Parkinson’s disease (PD) is characterized by a progressive loss of dopaminergic neurons in the substantia nigra. Recent literature has proposed two subgroups PD. The “body-first subtype” associated with prodrome isolated REM-sleep Behavior Disorder (iRBD) and relatively symmetric brain degeneration. “brain-first suggested to have more asymmetric degeneration prodromal stage without RBD. This study aims investigate difference symmetry pattern presumed body brain-first PD subtypes. We...

10.1038/s41531-024-00685-3 article EN cc-by npj Parkinson s Disease 2024-03-30

Abstract Isolated REM Sleep Behavior Disorder (iRBD) is considered a prodrome of Parkinson’s disease (PD). We investigate whether the potentially disease-modifying compound acetyl- DL -leucine (ADLL; 5 g/d) has an effect on prodromal PD progression in 2 iRBD-patients. Outcome parameters are RBD-severity sum-score (RBD-SS-3), dopamine-transporter single-photon emission computerized tomography (DAT-SPECT) and metabolic “Parkinson-Disease-related-Pattern (PDRP)”-z-score 18 F-fluorodeoxyglucose...

10.1038/s41467-024-51502-7 article EN cc-by Nature Communications 2024-09-02

<title>Abstract</title> Purpose: Center-specific effects in PET brain scans arise due to differences technical and procedural aspects. This restricts the merging of data between centers introduces source-specific bias. Methods: We demonstrate use recently proposed machine learning method Iterated Relevance Matrix Analysis (IRMA) for harmonization center-specific <sup>18</sup>F-Fluorodeoxyglucose (<sup>18</sup>F-FDG) scans. The center difference is learned by applying IRMA on PCA-based...

10.21203/rs.3.rs-5825843/v1 preprint EN cc-by Research Square (Research Square) 2025-01-15

Parkinson's disease (PD) is characterized by heterogeneity in clinical syndromes, prognosis, and pathophysiology mechanisms. Gender differences neural anatomy function are emerging as fundamental determinants of phenotypic variability. Different subtypes, defined mild motor predominant, intermediate, diffuse-malignant, have been recently proposed PD. This study investigated gender influence on features, dopaminergic dysfunction, connectivity patients with de novo idiopathic PD stratified...

10.1016/j.nbd.2022.105668 article EN cc-by-nc-nd Neurobiology of Disease 2022-02-24

Isolated REM sleep behaviour disorder (iRBD) patients are at high risk of developing clinical syndromes the α-synuclein spectrum. Progression markers needed to determine neurodegenerative changes and predict their conversion. Brain imaging with 18F-FDG PET in iRBD is promising, but longitudinal studies scarce. We investigated regional brain over time, related phenoconversion.Twenty underwent two consecutive scans assessments (3.7 ± 0.6 years apart). Seventeen also 123I-MIBG 123I-FP-CIT SPECT...

10.1007/s00259-023-06289-y article EN cc-by European Journal of Nuclear Medicine and Molecular Imaging 2023-06-13

Abstract The most common genetic risk factors for Parkinson’s disease are GBA1 mutations, encoding the lysosomal enzyme glucocerebrosidase. Patients with mutations (GBA-PD) exhibit earlier age of onset and faster progression more severe cognitive impairments, postural instability gait problems. These GBA-PD features suggest cholinergic system pathologies. PET imaging vesicular acetylcholine transporter ligand 18F-F-fluoroethoxybenzovesamicol (18F-FEOBV PET) provides opportunity to...

10.1093/brain/awad323 article EN cc-by Brain 2023-09-25

Understanding the neural underpinning of human gait and balance is one most pertinent challenges for 21st-century translational neuroscience due to profound impact that falls mobility disturbances have on our aging population. Posture control does not happen automatically, as previously believed, but rather requires continuous involvement central nervous mechanisms. To effectively exert over body, brain must integrate multiple streams sensory information, including visual, vestibular,...

10.4103/nrr.nrr-d-23-01484 article EN cc-by-nc-sa Neural Regeneration Research 2024-03-01

ABSTRACT Background Glucosylceramidase ( GBA ) mutations are considered the most common genetic risk factors for developing Parkinson's disease (PD). Objectives We aimed to assess, at different time points, integrity of brain striatal and extra‐striatal dopamine pathways clinical phenotype a group PD subjects bearing heterozygous (GBA‐PD), compared with idiopathic patients (iPD) stratified by age onset. A longitudinal approach was adopted evaluate progression over 123 I‐FP‐CIT SPECT imaging...

10.1002/mds.28818 article EN Movement Disorders 2021-10-01

Abstract Background The amnestic presentation of mild cognitive impairment (aMCI) represents the most common prodromal stage Alzheimer's disease (AD) dementia. There is, however, some evidence aMCI with typical syndrome but showing long‐term clinical stability. ability to predict stability or progression dementia in condition is important, particularly for selection candidates trials. We aimed establish role vivo biomarkers, as assessed by cerebrospinal fluid (CSF) measures and [ 18...

10.1111/ene.14639 article EN European Journal of Neurology 2020-11-13

Previous evidence suggests that the derangement of large-scale brain networks reflects structural, molecular, and functional mechanisms underlying neurodegenerative diseases. Although alterations multiple in Parkinson's disease (PD) Dementia with Lewy Bodies (DLB) are reported, a comprehensive study on connectivity reconfiguration starting from preclinical phase is still lacking. We aimed to investigate shared disease-specific changes across (LB) disorders spectrum using metabolic approach....

10.3389/fnins.2022.930735 article EN cc-by Frontiers in Neuroscience 2022-08-08

Abstract Background and purpose Isolated rapid eye movement sleep behaviour disorder (iRBD) is a parasomnia, recently recognized as risk factor for progression to Parkinson's disease, dementia with Lewy body multiple system atrophy. Biomarker studies in iRBD are relevant due lack of evidence this condition. The identification biomarkers able predict synucleinopathy diseases critical iRBD. Fluorodeoxyglucose‐positron emission tomography (FDG‐PET) imaging might provide information about...

10.1111/ene.14215 article EN European Journal of Neurology 2020-03-14

Brain imaging with [18F]FDG-PET can support the diagnostic work-up of patients α-synucleinopathies. Validated data analysis approaches are necessary to evaluate disease-specific brain metabolism patterns in neurodegenerative disorders. This study compared univariate Statistical Parametric Mapping (SPM) single-subject procedure and multivariate Scaled Subprofile Model/Principal Component Analysis (SSM/PCA) a cohort α-synucleinopathies.We included scans 122 subjects within α-synucleinopathy...

10.1016/j.nicl.2023.103475 article EN cc-by NeuroImage Clinical 2023-01-01
Coming Soon ...